Document is current

Documents that mention this clinical trial

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes
https://doi.org/10.2337/dc18-2361

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
https://doi.org/10.1007/s13300-018-0430-4

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
https://doi.org/10.1136/bmjdrc-2021-002339

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
https://doi.org/10.1186/s12933-019-0960-8

Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1
https://doi.org/10.1016/j.ahj.2016.06.004

Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis
https://doi.org/10.2337/db18-1065-p

21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial
https://doi.org/10.2337/db20-21-lb